Literature DB >> 18812520

The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity.

Maya Remington1, Jana Chtchetinin, Karen Ancheta, Phioanh Leia Nghiemphu, Timothy Cloughesy, Albert Lai.   

Abstract

First-line therapy for patients with glioblastoma multiforme includes treatment with radiation and temozolomide (TMZ), an oral DNA alkylating chemotherapy. Sensitivity of glioma cells to TMZ is dependent on the level of cellular O(6)-methylguanine-DNA methyltransferase (MGMT) repair activity. Several common coding-region polymorphisms in the MGMT gene (L84F and the linked pair I143V/K178R) modify functional characteristics of MGMT and cancer risk. To determine whether these polymorphic changes influence the ability of MGMT to protect glioma cells from TMZ, we stably overexpressed enhanced green fluorescent protein (eGFP)-tagged MGMT constructs in U87MG glioma cells. We confirmed that the wild-type (WT) eGFP-MGMT protein is properly localized within the nucleus and found that L84F, I143V/K178R, and L84F/I143V/K178R eGFP-MGMT variants exhibited nuclear localization patterns indistinguishable from WT. Using MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide] proliferation and clonogenic survival assays, we confirmed that WT cells expressing eGFP-MGMT are resistant to TMZ treatment compared with control U87MG cells, and that each of the polymorphic eGFP-MGMT variants confers similar resistance to TMZ. However, upon exposure to O(6)-benzylguanine (O(6)-BG), a synthetic MGMT inhibitor, the L84F and L84F/I143V/K178R variants were degraded more rapidly than WT or I143V/K178R in a proteasome-dependent manner. Despite the increased O(6)-BG- stimulated protein turnover caused by the L84F alteration, cells expressing L84F eGFP-MGMT did not exhibit altered sensitivity to the combination of O(6)-BG and TMZ compared with WT cells. In conclusion, we demonstrated that the L84F polymorphic variant has altered protein turnover without modifying sensitivity of U87MG cells to TMZ or combined TMZ and O(6)-BG. These findings may provide a clue to determining the clinical significance of MGMT coding-region polymorphisms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18812520      PMCID: PMC2718956          DOI: 10.1215/15228517-2008-080

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  32 in total

1.  Inactivation and degradation of O(6)-alkylguanine-DNA alkyltransferase after reaction with nitric oxide.

Authors:  Liping Liu; Meng Xu-Welliver; Sreenivas Kanugula; Anthony E Pegg
Journal:  Cancer Res       Date:  2002-06-01       Impact factor: 12.701

2.  The modified human DNA repair enzyme O(6)-methylguanine-DNA methyltransferase is a negative regulator of estrogen receptor-mediated transcription upon alkylation DNA damage.

Authors:  A K Teo; H K Oh; R B Ali; B F Li
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

3.  Differential inactivation of polymorphic variants of human O6-alkylguanine-DNA alkyltransferase.

Authors:  Qingming Fang; Natalia A Loktionova; Robert C Moschel; Sahar Javanmard; Gary T Pauly; Anthony E Pegg
Journal:  Biochem Pharmacol       Date:  2007-10-02       Impact factor: 5.858

4.  Induction of the DNA repair gene O6-methylguanine-DNA methyltransferase by dexamethasone in glioblastomas.

Authors:  Shigeo Ueda; Toshihiro Mineta; Yukiko Nakahara; Hiroaki Okamoto; Tetsuya Shiraishi; Kazuo Tabuchi
Journal:  J Neurosurg       Date:  2004-10       Impact factor: 5.115

5.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

6.  A genotype of the polymorphic DNA repair gene MGMT is associated with de novo glioblastoma.

Authors:  Ryo Inoue; Mitsuo Isono; Masako Abe; Tatsuya Abe; Hidenori Kobayashi
Journal:  Neurol Res       Date:  2003-12       Impact factor: 2.448

7.  Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells.

Authors:  M Figul; A Söling; H J Dong; T-C Chou; N G Rainov
Journal:  Cancer Chemother Pharmacol       Date:  2003-04-11       Impact factor: 3.333

8.  Ubiquitination-dependent proteolysis of O6-methylguanine-DNA methyltransferase in human and murine tumor cells following inactivation with O6-benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea.

Authors:  K S Srivenugopal; X H Yuan; H S Friedman; F Ali-Osman
Journal:  Biochemistry       Date:  1996-01-30       Impact factor: 3.162

9.  Nuclear-localizing O6-benzylguanine-resistant GFP-MGMT fusion protein as a novel in vivo selection marker.

Authors:  Uimook Choi; Suk See DeRavin; Kouhei Yamashita; Narda Whiting-Theobald; Gilda F Linton; Natalia A Loktionova; Anthony E Pegg; Harry L Malech
Journal:  Exp Hematol       Date:  2004-08       Impact factor: 3.084

10.  O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma.

Authors:  S Ma; S Egyházi; T Ueno; C Lindholm; E L Kreklau; U Stierner; U Ringborg; J Hansson
Journal:  Br J Cancer       Date:  2003-10-20       Impact factor: 7.640

View more
  5 in total

1.  Impact of rs12917 MGMT Polymorphism on [18F]FDG-PET Response in Pediatric Hodgkin Lymphoma (PHL).

Authors:  Stefanie Kewitz-Hempel; Lars Kurch; Michaela Cepelova; Ines Volkmer; Axel Sauerbrey; Elke Conrad; Stephanie Knirsch; Gabriele Pöpperl; Daniel Steinbach; Ambros J Beer; Christof M Kramm; Carsten-Oliver Sahlmann; Bernhard Erdlenbruch; Wolf-Dieter Reinbold; Andreas Odparlik; Osama Sabri; Regine Kluge; Martin S Staege
Journal:  Mol Imaging Biol       Date:  2019-12       Impact factor: 3.488

Review 2.  Multifaceted roles of alkyltransferase and related proteins in DNA repair, DNA damage, resistance to chemotherapy, and research tools.

Authors:  Anthony E Pegg
Journal:  Chem Res Toxicol       Date:  2011-04-28       Impact factor: 3.739

3.  Tyrosine-dependent basolateral targeting of human connexin43-eYFP in Madin-Darby canine kidney cells can be disrupted by the oculodentodigital dysplasia mutation L90V.

Authors:  Jana Chtchetinin; Wes D Gifford; Sichen Li; William A Paznekas; Ethylin Wang Jabs; Albert Lai
Journal:  FEBS J       Date:  2009-10-27       Impact factor: 5.542

Review 4.  Impact of temozolomide on immune response during malignant glioma chemotherapy.

Authors:  Sadhak Sengupta; Jaclyn Marrinan; Caroline Frishman; Prakash Sampath
Journal:  Clin Dev Immunol       Date:  2012-10-24

5.  Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.

Authors:  Sichen Li; Arthur P Chou; Weidong Chen; Ruihuan Chen; Yuzhong Deng; Heidi S Phillips; Julia Selfridge; Mira Zurayk; Jerry J Lou; Richard G Everson; Kuan-Chung Wu; Kym F Faull; Timothy Cloughesy; Linda M Liau; Albert Lai
Journal:  Neuro Oncol       Date:  2012-10-31       Impact factor: 13.029

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.